PGT-A Upgrade International Multicenter Observational Clinical Trial
Summary
The NIH ClinicalTrials.gov registry has recorded a new international multicenter observational clinical trial (NCT07533630) evaluating PGT-A upgrade testing for preimplantation genetic testing in assisted reproductive technology. The study will enroll patients from seven domestic and international centers to assess embryo utilization rates and clinical outcomes including birth defects following PGT-A upgrade testing. Patient enrollment is expected to be completed within one year.
What changed
NIH registered a new observational clinical trial to evaluate PGT-A upgrade testing capable of detecting embryonic chromosomal aneuploidy, mosaicism, microdeletions/microduplications, heteroploidy, and loss of heterozygosity in a single assay. The international multicenter study aims to reduce miscarriage and birth defects while improving embryo selection in infertility treatment.
Affected parties including healthcare providers specializing in assisted reproductive technology, clinical investigators, and patients undergoing PGT-A should note this trial as a potential participation opportunity. The study will provide molecular genetic evidence to inform clinical management of atypically fertilized embryos and optimize mosaic embryo transfer strategies.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Prospective International Multi-center Clinical Trial of PGT-A Upgrade
Observational NCT07533630 Kind: OBSERVATIONAL Apr 16, 2026
Abstract
The goals of this international multicenter cross-sectional study are:
- To provide patients with a comprehensive PGT solution capable of simultaneously detecting embryonic chromosomal aneuploidy, mosaicism, microdeletions/ microduplications, heteroploidy, and heterozygosity (LOH) in a single assay, thereby reducing miscarriage and birth defects;
- To perform PGT analysis on abnormally fertilized embryos, select euploid embryos with normal ploidy, and calculate embryo utilization rates;
- To reduce the false-positive rate through confirmation of mosaic embryos and subsequent analysis of its origin, thereby minimizing embryo wastage;
- To provide molecular genetic evidence for expert consensus on clinical management of atypically fertilized embryos, of pathogenic/likely pathogenic small CNVs, optimize mosaic embryo transfer strategies, and inform preconception intervention;
- To enhance international PGT testing standards through international multi-center collaboration.
The study will enroll patients undergoing PGT-A from seven domestic and international centers, with patient enrollment expected to be completed within one year. PGT-A upgrade testing will be performed on embryos from enrolled patients, and the incidence rates of Incidence of microdeletions/microduplications, heteroploidy, LOH will be statistically analyzed. All patients who undergo embryo transfer will be followed up for clinical outcomes and birth defects.
Conditions: Infertility Assisted Reproductive Technology
Interventions: PGT-A upgrade
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.